# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0212 |
| Population Package | PP-0212 |
| Title | Anti-angiogenic Therapy |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Last Updated | 2026-08-09 |

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | Package answers what anti-angiogenic therapy is, how it works, when it is used, what benefit is demonstrated and what limitations/safety considerations matter. |
| Scope respected | PASS | Anti-angiogenic treatment is the substantive owner; broad targeted therapy, biomarker testing, dosing and toxicity algorithms remain excluded. |
| Core drug ownership clear | PASS | Ramucirumab is the principal established gastric-cancer example without collapsing the package into a drug-prescribing monograph. |
| Mechanism coverage complete | PASS | Angiogenesis, VEGF/VEGFR and VEGFR-2 are explained at the required conceptual depth. |
| Clinical setting coverage complete | PASS | Previously treated advanced/metastatic gastric/EGJ disease and subsequent-line context are explicit. |
| Trial evidence coverage complete | PASS | REGARD, RAINBOW and RAINFALL are all represented. |
| Quantitative evidence preserved | PASS | Key OS, HR, PFS and ORR findings are retained where supported. |
| Negative evidence preserved | PASS | RAINFALL is explicitly included to prevent overgeneralization to first-line treatment. |
| Treatment paradigms complete | PASS | Monotherapy, paclitaxel combination, FOLFIRI combination and irinotecan combination are addressed at appropriate conceptual depth. |
| Safety coverage complete | PASS | Hypertension, bleeding, thrombosis, GI perforation and wound healing are addressed. |
| Patient-facing content complete | PASS | Misconceptions, key messages and patient questions are included. |
| Knowledge Graph complete | PASS | Prerequisite, related, downstream and delegated relationships are defined. |
| Boundary ownership controlled | PASS | Scope is consistent with adjacent PP architecture. |

### Content QA narrative

The CKO is not a short executive summary. It contains a complete patient-facing learning sequence from biological rationale through treatment mechanism, clinical role, randomized evidence, treatment-line distinctions, safety and patient interpretation.

The evidence package preserves numerical trial evidence rather than replacing it with generic statements such as “clinical trials showed benefit.”

The package also preserves negative evidence because omission of RAINFALL would create a clinically misleading impression that anti-angiogenic therapy is appropriate in every treatment line.

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Scientifically accurate within source-supported scope | PASS | Claims are grounded in supplied NCCN, NCI and ACS materials. |
| Current guideline positioning preserved | PASS | NCCN v2.2026 is treated as the highest-priority disease-specific source. |
| Ramucirumab target correct | PASS | VEGFR-2 is identified as the target. |
| REGARD population correct | PASS | 355 stage IV gastric/GEJ patients after first-line 5-FU/platinum-containing treatment. |
| REGARD OS data correct | PASS | 5.2 vs 3.8 months; HR 0.776; P=.047. |
| RAINBOW population correct | PASS | 665 metastatic gastric/EGJ patients progressing on first-line chemotherapy. |
| RAINBOW OS data correct | PASS | 9.6/9.63 vs 7.4/7.36 months depending source precision. |
| RAINBOW PFS/ORR data correct | PASS | 4.4 vs 2.86 months and 28% vs 6% preserved from NCCN. |
| RAINFALL interpretation correct | PASS | Routine first-line addition is not recommended in current supplied NCCN guidance. |
| Guideline category distinction preserved | PASS | Category 1 preferred vs category 1 other recommended vs category 2A options are not flattened. |
| No unsupported biomarker requirement | PASS | No invented VEGF/VEGFR companion biomarker. |
| Safety claims supported | PASS | Hypertension and serious vascular/GI/wound-healing risks are source-supported. |
| No unsafe medical advice | PASS | No individualized prescribing or treatment-change instruction. |
| Evidence limitations preserved | PASS | Trial population, regimen-specific and evidence-level limitations are explicit. |

### Clinical QA narrative

The clinical content is anchored first to the supplied NCCN v2.2026 guideline. NCI PDQ is used as an independent evidence synthesis for REGARD and RAINBOW. ACS is used primarily for patient-facing mechanism and safety explanation.

The package does not silently replace the project source base with general medical knowledge.

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Medical terms are explained at first use. |
| Patient-friendly wording | PASS | Concepts are explained without unnecessary technical jargon. |
| Learning progression logical | PASS | Biology → target → drug → treatment setting → evidence → safety → interpretation. |
| Technical terminology controlled | PASS | VEGF, VEGFR, VEGFR-2, OS, PFS and ORR are introduced in context. |
| Common misconceptions addressed | PASS | Dedicated misconception section prevents predictable misunderstandings. |
| Patient questions practical | PASS | Questions address treatment rationale, regimen, benefit, safety and sequencing context. |
| Uncertainty communicated | PASS | Trial population-level effects are distinguished from individual outcomes. |
| Negative evidence communicated | PASS | RAINFALL prevents overpromising. |
| No overpromising | PASS | Package does not equate targeted therapy with guaranteed response or cure. |
| Appropriate educational boundary | PASS | No attempt to replace clinical decision-making. |

### Educational QA narrative

The package preserves the established Gold patient-facing style: short explanatory units, question-oriented concepts, explicit misconceptions, clinically meaningful messages and practical questions.

The explanation of targeted therapy versus biomarker-selected therapy is intentionally retained because it prevents the patient from incorrectly applying the architecture of HER2/CLDN18.2 treatment to ramucirumab.

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure preserved. |
| Approved Decision Batch respected | PASS | Scope is implemented without reopening locked decisions. |
| Source-First rule respected | PASS | PP-specific clinical sources were searched before synthesis. |
| Gold reference structure preserved | PASS | Artifact structures follow supplied Gold references and specification. |
| Gold depth integrity preserved | PASS | Content is full-depth and not compacted into an executive summary. |
| Artifact naming compliant | PASS | Standard artifact names used. |
| Versioning compliant | PASS | Version 1.0.0 used. |
| Knowledge Graph complete | PASS | Relationships are clinically meaningful and not artificial. |
| Boundary structure compliant | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP preserved. |
| Adjacent PP overlap checked | PASS | PP-0208 through PP-0213 treatment architecture reviewed. |
| Repository-ready structure | PASS | Four Markdown artifacts packaged in one ZIP. |

---

# Clinical Safety Review

| Item | Result | QA Note |
|---|---|---|
| No individualized treatment recommendation | PASS | Educational treatment literacy only. |
| No instruction to start/stop/change treatment | PASS | Explicitly excluded. |
| No individualized prognosis | PASS | Trial results are population-level. |
| No dosing instructions | PASS | Dosing/administration excluded. |
| No toxicity-management algorithm | PASS | Safety awareness only. |
| No unsupported biomarker threshold | PASS | No invented VEGF/VEGFR selection threshold. |
| No universal first-line claim | PASS | RAINFALL limitation preserved. |
| No universal subsequent-line claim | PASS | Treatment is context-dependent. |
| No claim that targeted means risk-free | PASS | Serious safety risks are described. |
| Appropriate clinician referral | PASS | Individual treatment decisions remain with care team. |

---

# Patient Misconception Review

## Misconception 1 — “Anti-angiogenic therapy simply starves the cancer.”

**PASS.**

The package explains angiogenic signaling rather than presenting an oversimplified physical starvation model.

## Misconception 2 — “Ramucirumab requires a VEGF-positive biomarker.”

**PASS.**

The package does not invent a companion biomarker and distinguishes target-directed treatment from conventional biomarker-selected therapy.

## Misconception 3 — “A targeted treatment should work in every treatment line.”

**PASS.**

RAINFALL is explicitly included.

## Misconception 4 — “Targeted treatment has no serious side effects.”

**PASS.**

Hypertension, bleeding, thrombosis, GI perforation and wound-healing problems are explicitly included.

## Misconception 5 — “Trial benefit means guaranteed individual benefit.”

**PASS.**

Population-level evidence is explicitly distinguished from individual outcomes.

---

# Adjacent PP Overlap Audit

| Adjacent PP | Ownership | PP-0212 Treatment |
|---|---|---|
| PP-0208 — Palliative Systemic Therapy | Overall palliative systemic-treatment framework | Use treatment-line context only; do not duplicate framework |
| PP-0209 — Targeted Therapy in Gastric Cancer | Targeted-therapy umbrella | Use umbrella concepts only; detailed anti-angiogenic content owned here |
| PP-0210 — HER2-targeted Therapy | HER2-specific treatment | Explicitly separated |
| PP-0211 — CLDN18.2-targeted Therapy | CLDN18.2-specific treatment | Explicitly separated |
| PP-0213 — Immunotherapy in Gastric Cancer | Immunotherapy branch | Explicitly separated |
| PP-0231 — Treatment-related Toxicity and Supportive Care | Detailed safety/supportive-care ownership | PP-0212 provides only treatment-specific safety awareness |

### Overlap conclusion

**PASS — no substantive duplicate ownership identified.**

---

# Evidence Traceability Audit

Every major clinical claim has a source role:

- mechanism → ACS;
- VEGFR-2 target → NCCN;
- REGARD → NCCN + NCI;
- RAINBOW → NCCN + NCI;
- RAINFALL → NCCN;
- current regimen positioning → NCCN;
- patient-facing safety → ACS/NCCN;
- treatment-context framing → NCI;
- boundary architecture → PP Registry/Governance.

**Result: PASS.**

---

# Numerical Evidence Audit

| Numerical Claim | Audit Result |
|---|---|
| REGARD n=355 | PASS |
| REGARD OS 5.2 vs 3.8 months | PASS |
| REGARD HR 0.776 | PASS |
| REGARD P=.047 | PASS |
| RAINBOW n=665 | PASS |
| RAINBOW OS 9.6/9.63 vs 7.4/7.36 months | PASS |
| RAINBOW HR 0.807 | PASS |
| RAINBOW P=.017 | PASS |
| RAINBOW PFS 4.4 vs 2.86 months | PASS |
| RAINBOW ORR 28% vs 6% | PASS |
| FOLFIRI retrospective cohort n=29 | PASS |
| FOLFIRI ORR 23% | PASS |
| FOLFIRI disease-control rate 79% | PASS |
| FOLFIRI median PFS 6 months | PASS |
| FOLFIRI median OS 13.4 months | PASS |

### Numerical interpretation rule

No numerical trial result is presented as an individualized prediction.

---

# Knowledge Graph Audit

## Prerequisite audit

PP-0208 and PP-0209 are meaningful prerequisites.

**PASS.**

## Related-node audit

PP-0210, PP-0211 and PP-0213–PP-0216 are clinically adjacent but retain separate ownership.

**PASS.**

## Downstream audit

Safety, response assessment, sequencing and treatment-change packages are appropriate downstream nodes.

**PASS.**

## Delegation audit

Delegations correspond to existing or logically distinct package ownership.

**PASS.**

---

# Gold Depth Integrity Review

## Required rule

Gold Reference Depth is a minimum standard.

The artifact set must not:

- compact;
- shorten;
- summarize;
- collapse substantive reasoning;
- reduce evidence detail;
- reduce QA depth;
- reduce Knowledge Graph detail;
- reduce patient-facing explanatory depth.

## Audit

### 01_CKO
**PASS** — full patient-facing educational progression, knowledge blocks, misconceptions, safety, patient questions and Knowledge Graph included.

### 02_KNOWLEDGE_PASSPORT
**PASS** — runtime relevance, knowledge units, evidence classification, governance metadata, Knowledge Graph, boundary map and safety rules included.

### 03_PRIMARY_EVIDENCE_PACKAGE
**PASS** — clinical question, scope, primary sources, hierarchy, evidence matrix, detailed appraisal, evidence limitations, gaps, update triggers, patient translation, traceability and boundary verification included.

### 04_QA_REPORT
**PASS** — four QA layers plus clinical safety, misconception, overlap, traceability, numerical, Knowledge Graph and package-integrity audits included.

### Overall

**PASS — Absolute Gold Depth preserved.**

---

# Source-First Audit

## Required sequence

1. Search PP-specific Source Files.
2. Establish exact clinical evidence.
3. Check governance and Gold references.
4. Check adjacent PP ownership.
5. Produce artifacts from the locked Decision Batch.

## Result

**PASS.**

The supplied NCCN, NCI and ACS materials were directly searched and used. The PP Registry and governance materials were checked for identity and boundaries.

No external web source was used to replace project evidence.

---

# Locked Decision Integrity

| Decision | Status |
|---|---|
| Concept-first, ramucirumab-centered | Preserved |
| VEGF/VEGFR conceptual biology | Preserved |
| VEGFR-2 target | Preserved |
| Subsequent-line core setting | Preserved |
| REGARD | Preserved |
| RAINBOW | Preserved |
| RAINFALL negative evidence | Preserved |
| Monotherapy + combination paradigms | Preserved |
| No invented companion biomarker | Preserved |
| Safety awareness | Preserved |
| Broad anti-angiogenic oncology excluded | Preserved |
| Adjacent PP boundaries | Preserved |

**Result: PASS — no locked decision reopened or materially altered.**

---

# Cross-artifact Consistency

| Cross-artifact item | Result |
|---|---|
| PP ID | PASS |
| Title | PASS |
| Atomic clinical question | PASS |
| Scope | PASS |
| Clinical role | PASS |
| Ramucirumab-centered treatment model | PASS |
| REGARD evidence | PASS |
| RAINBOW evidence | PASS |
| RAINFALL evidence | PASS |
| Safety | PASS |
| Knowledge Graph | PASS |
| Boundary | PASS |
| Exclusions | PASS |
| Delegations | PASS |
| Version | PASS |

---

# Package Integrity

| Artifact | Present | Structure | Status |
|---|---|---|---|
| 01_CKO.md | YES | Gold structure | PASS |
| 02_KNOWLEDGE_PASSPORT.md | YES | Gold structure | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | YES | Gold structure | PASS |
| 04_QA_REPORT.md | YES | Gold structure | PASS |

The four artifacts are packaged together as a single PP-0212 Gold ZIP.

---

# Final QA Determination

PP-0212 satisfies:

- Source-First evidence requirements;
- approved and locked Decision Batch;
- Gold structural requirements;
- Absolute Gold Depth requirement;
- clinical evidence traceability;
- patient-facing educational requirements;
- adjacent PP boundary requirements;
- clinical safety requirements;
- Knowledge Graph requirements;
- four-artifact production requirements.

**QA result: PASS.**

---

# Final Status

**PASS — GOLD — READY FOR INTEGRATION.**
